跳至主要内容
临床试验/KCT0004083
KCT0004083招募中未知

Randomized, Double-blind placebo-controlled study of Brintelix for the treatment for depression in Alzheimer's Disease.

Hallym University Medical Center- Chuncheon0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
60(Year) 至 o Limit(—)
性别
All

入选标准

  • ?Patients aged 60 years or older who have voluntarily participated in the study and signed an agreement
  • ?Patients who meet the criteria for Alzheimer's dementia of NINCDS-ADRDA
  • ?Patients with three or more symptoms on Olin Diagnosis Criteria for Depression in Alzheimer's Dementia
  • ?Patients with a CDR score of 0.5 to 2
  • ?Patients with a MMSE-KC score of 10 to 26
  • ?Patients with a SGDS-K score of 5 or more
  • ?Patients with care giver who can accompany all study visits

排除标准

  • ?Patient with a history of taking antidepressants within 4 weeks
  • ?Patient who was given memantine in at least four weeks
  • ?Patients with other major mental disorders
  • ?Patients with triple normal levels of AST or ALT liver function
  • ?Patient showing evidence of severe cerebrovascular disease.
  • ?Patient showing evidence of critical or unstable internal medicine (e.g., uncontrolled diabetes with symptoms)
  • ?Patients with evidence of Parkinson's disease, stroke, brain tumor or normal brain pressure hydrocephalus
  • ?Patient with a history of alcohol or other drug abuse

研究者

发起方
Hallym University Medical Center- Chuncheon

相似试验